China Grand Pharmaceutical and Healthcare : Enterprises Ranks 13 at Top 100 Accolade in China’s Pharmaceutical Industry

> China Grand Enterprises Ranks 13 at Top 100 Accol ade in China's Pharmaceutical Industry Date: 5 September, 2017 Location: Hong Kong

The 34th China Pharmaceutical Industry Information Annual Conference 2017 was recently held in Chengdu by China National Pharmaceutical Industry Information Center. During the Conference, "Top Accolade in China's Pharmaceutical Industry in 2016" was officially announced. China Grand Enterprises, Inc. (China Grand Enterprises) ranks at 13 (exclude Hangzhou East China Pharmaceutical Group Co., Ltd which was elsewhere ranked No.20 in the same ranking list).

According to the statistics and analysis from China National Pharmaceutical Industry Information Center, comparing to the standard calculation, the total revenue of the Top 100 pharmaceutical enterprises in 2016 was RMB680.9 billion, YoY 11.1%, and the minimum threshold for the finalist reached to RMB2.4billion.

China Grand Enterprises has attached great importance to the pharmaceutical and healthcare business, actively support the development of its pharmaceutical sector, since year 2014, paying more attention to the international business opportunities. China Grand Pharmaceutical and Healthcare Holdings Limited (China Grand Pharm, stockcode: 00512) is the only international capital market platform to China Grand Enterprises. China Grand Pharm mainly engages in ENT, ophthalmology and cardiovascular segments with pharmaceutical preparations and medical devices products. The total revenue reached HKD3.7 billion in 2016, YoY 13.9%, if taken out the depreciation effect of RMB, the revenue was increased by 20.2%. The revenue of the first half of 2017 achieved HKD2.3 billion, YoY 27.7%. China Grand Pharm launched a number of core products, such as Qie Nuo, Xin Wei Ning and Li Shuan, etc, 203 products are enlisted on the latest version of the National Medical Insurance Drug Catalogs 2017, this ensures the quality of the products and professions have been widely recognized by the market. At present, pharmaceutical preparations and medical devices products accounted for more than half of the revenue, the Company has always attached great importance to product reserves, will also introduce the world's most advanced cardiovascular interventional medical equipment - a series of high-end drug-eluting balloon products, in the international strategy, as well as the international market expansion, with more success records for the majority of shareholders to bring huge benefits return.

In the forthcoming five years, to further improve the operational efficiency and profitability of enterprises and the synergies between affiliated companies, and actively explore and grasp the

market opportunities, in-depth understanding of China's pharmaceutical industry development and policy changes to achieve the goal of revenue of ten billion of enterprises.